- Trial phase
- Approved (commercial stage)
- Time to market
- Already approved and commercialized. The next label expansion (infant atopic dermatitis) has a PDUFA decision date of February 23, 2027.
- Why 7/10
- The next hard catalyst is the FDA PDUFA decision on February 23, 2027 for the sNDA expanding ZORYVE cream 0.05% to infants aged 3-24 months with atopic dermatitis. This is a label expansion for an already-approved, revenue-generating drug, so the binary outcome is meaningful but not make-or-break for the company. ImpactScore 7 reflects a dated binary within ~6 months on the company's lead asset that drives most of the thesis.
The next hard catalyst is the FDA PDUFA decision on February 23, 2027 for ZORYVE cream 0.05% in infants aged 3-24 months with atopic dermatitis. Approval would expand the addressable patient population and support the company's 2027 revenue inflection narrative; a CRL would remove that near-term growth driver but not threaten the core commercial business, which is already generating over $500M in annual revenue.
Price Chart
Executive Summary
ZORYVE (roflumilast) is Arcutis Biotherapeutics' (ARQT) only marketed product, a once-daily topical steroid-free PDE4 inhibitor approved in cream and foam formulations for plaque psoriasis, atopic dermatitis, and seborrheic dermatitis. The drug is already generating substantial and growing revenue ($143.9M in Q3 2026, up 45% YoY) with full-year 2026 guidance raised to $535-545M. The next major catalyst is the FDA PDUFA decision on February 23, 2027 for label expansion of ZORYVE cream 0.05% to infants aged 3-24 months with atopic dermatitis. The company is also advancing a Phase 3 trial in moderate to severe atopic dermatitis and a Phase 2 trial in chronic hand eczema. Analyst consensus is strongly bullish (12 Buy/Strong Buy, mean PT $40.38, 46.7% upside), though insider selling and competitive pressure are notable risks.
How It Works
ZORYVE (roflumilast) is a topical cream or foam that you apply directly to the skin. It works by blocking an enzyme called PDE4, which reduces inflammation in the skin. Unlike steroid creams, it is steroid-free and can be used on any part of the body without restrictions on how long it can be used. It is applied once daily.
Trial Status
ZORYVE is approved across multiple indications and formulations. The sNDA for infant atopic dermatitis (ages 3-24 months) is under FDA review with a PDUFA date of February 23, 2027. A Phase 3 trial (INTEGUMENT-3) for ZORYVE cream 0.3% in moderate to severe atopic dermatitis began enrolling in November 2026. A Phase 2 trial of ZORYVE foam 0.3% for chronic hand eczema is ongoing with topline results on track.
The Two-Sided Case
Upcoming Catalysts
- FDA PDUFA decision on February 23, 2027 for ZORYVE cream 0.05% in infants aged 3-24 months with atopic dermatitis
- Topline results from Phase 2 trial of ZORYVE foam 0.3% for chronic hand eczema (timing not specified but 'on track' per Q3 2026 update)
- Enrollment and potential interim data from Phase 3 INTEGUMENT-3 trial of ZORYVE cream 0.3% in moderate to severe atopic dermatitis
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Arcutis Biotherapeutics, Inc. Press Release ARQT ·Originating report